Schroder Investment Management Group
SYRE icon

Schroder Investment Management Group’s Spyre Therapeutics SYRE Stock Holding History

Schroder Investment Management Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.02M Sell
44,586
-19,098
-30% -$1.39M ﹤0.01% 818
2026
Q1 		$2.89M Buy
63,684
+2,110
+3% +$79.5K ﹤0.01% 863
2025
Q4 		$1.96M Sell
61,574
-46,164
-43% -$1.21M ﹤0.01% 893
2025
Q3 		$1.76M Sell
107,738
-21,820
-17% -$356K ﹤0.01% 953
2025
Q2 		$1.97M Buy
129,558
+21,054
+19% +$312K ﹤0.01% 911
2025
Q1 		$1.95M Sell
108,504
-5,116
-5% -$106K ﹤0.01% 911
2024
Q4 		$2.56M Buy
+113,620
New +$3.33M ﹤0.01% 887

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Schroder Investment Management Group's SYRE Position: Q2 2026 in Review

Schroder Investment Management Group reduced its Spyre Therapeutics (SYRE) stake by 30% in Q2 2026, selling an estimated $1.39M and leaving 44,586 shares worth $4.02M. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Schroder Investment Management Group first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Schroder Investment Management Group held 44,586 shares of Spyre Therapeutics worth $4.02M as of Q2 2026.
  • Schroder Investment Management Group sold 19,098 Spyre Therapeutics shares in Q2 2026, an estimated $1.39M.
  • Spyre Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #818 holding.
  • Schroder Investment Management Group first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.